Rome Health adopts new lung cancer tracking software to help patients receive critical follow-ups
Rome Health now has advanced tracking software to help ensure that eligible patients receive critical screenings and follow up to assist in the early detection of lung cancer.
This item is available in full to subscribers.
Never miss a story
Subscribe now to get unlimited access to our digital content
Rome Health adopts new lung cancer tracking software to help patients receive critical follow-ups
ROME — Rome Health now has advanced tracking software to help ensure that eligible patients receive critical screenings and follow up to assist in the early detection of lung cancer. More people are now eligible for low-dose lung CT screening under the expanded guidelines from the U.S. Preventative Services Task Force.
Rome Health has adopted Volpara Lung software, a comprehensive lung health tracking and management system.
“Lung cancer screening is essential care, especially for high-risk patients,” said Dr. John Restivo, chairman of medical imaging at Rome Health.
“The newly expanded guidelines include a broader population than ever before and we need to spread the message that lung cancer extends beyond smokers and previous smokers: there are many other people at risk for lung cancer. Volpara Lung software makes it easy for us to track screened patients, ensuring they receive critical follow-ups and to notify providers of current recommended guidelines for at risk patients,” Restivo added.
For both smokers and non-smokers, it is essential to detect lung cancer early, when it is still treatable. The importance of early detection helped inform the recent decision by the United States Preventive Services Task Force to broaden the patient population eligible to receive low-dose lung CT screening.
Now, those who are between 50 and 80 years of age, who currently smoke or have quit smoking in the past 15 years and who have a 20 pack-year smoking history are eligible for a screening.
Lung cancer is the leading cause of cancer-related deaths in the United States, with over 350 deaths per day predicted in 2022. Though it is often considered a smoker’s disease, nearly 20% of patients who develop lung cancer have never smoked a cigarette.
Volpara Lung is designed to streamline and enrich lung screening through time-saving processes and automation. Using Volpara Lung as a one-stop solution, healthcare providers can submit all necessary data to the American College of Radiology Lung Cancer Screening Registry and generate over 40 statistical lung cancer screening reports that provide clear, real-time patient insights.
Rome Health’s team of committed imaging professionals use their expertise to offer top-quality care. Volpara Lung software will empower them to find lung cancers earlier and more easily track at-risk individuals.
Comments
No comments on this item Please log in to comment by clicking here